REGENXBIO price to sales ratio RGNX

Market value divided by revenue over the last twelve months, since 2016.

Today, Oct 23, 2026: 2.5×
10-year median: 9.3×
Against its 10-year history: 7th; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.8× to 145×
Peer median: 3.6×

REGENXBIO's price to sales ratio is 2.5× as of Oct 23, 2026.

That is below its ten-year median of 9.3×, lower than on 93% of days in the last ten years.

Over that time it ranged from 1.8× in May 2022 to 145× in Jun 2017.

The median for 4 biotech stocks of a similar size is 3.6×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.5×	2.3×	8.2×
2025	4.4×	2.5×	6.3×
2024	4.4×	4.4×	11.2×
2023	7.9×	1.9×	9.4×
2022	2.0×	1.8×	13.4×
2021	15.0×	7.8×	17.9×
2020	11.7×	7.7×	43.7×
2019	23.3×	8.6×	27.2×
2018	8.3×	7.8×	121×
2017	103×	62.5×	145×
2016	67.0×	28.4×	84.1×

Against its peers

Companies in Biotechnology nearest REGENXBIO's size, closest first, today.

Company	Price to sales ratio
RGNXREGENXBIO	2.5×
MGTXMeiraGTx	2.2×
PLXProtalix BioTherapeutics	2.5×
VCELVericel	7.1×
ADMAAdma Biologics	4.7×
Peer median	3.6×

Where REGENXBIO ranks

#9of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on REGENXBIO

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.